All 1 Debates between Sadik Al-Hassan and Zubir Ahmed

Tue 7th Jan 2025

Tobacco and Vapes Bill (Second sitting)

Debate between Sadik Al-Hassan and Zubir Ahmed
Sadik Al-Hassan Portrait Sadik Al-Hassan
- Hansard - -

Q I thought you said that there are no licensed products on the market?

Dr Laura Squire: There are not, which is why that is the way we would prefer to do it. Again, if we licensed these consumer products as a medicine, there are very strict requirements on labelling and on what needs to be given to the patient to explain what the product is and its risks. That is not there with these consumer cigarettes. It is going to get stricter under the new rules, but my preference would be that we give people more information.

Zubir Ahmed Portrait Dr Ahmed
- Hansard - - - Excerpts

Q Thank you, Dr Squire, for being with us. The Royal College of Physicians has called for manufacturers to limit the production of toxic substances and for the MHRA to independently verify some of the contents of e-cigarettes. Do you think that that can be achieved through the measures in the Bill as it stands?

Dr Laura Squire: It depends on what happens with the actual regulations. At the moment, we do not have powers to test consumer e-cigarettes—that power sits with trading standards. Again, if we license something as a medicine, we go into absolute detail about what is in it. At the moment, it depends on what is in the regulations that come round. We do not do testing at the moment, and it would be important to think about the point at which any testing is done. If it is done at the point where something goes on to the register, that is fine and it tells you that the sample we saw at that point was compliant. But what happens later down the track? I think the role that trading standards has in doing that testing is really important, because it can do it post-market at any point. The question really is about the role of the MHRA—a medicines and healthcare products agency. Is it getting deeper into these consumer products where the risk is not outweighed by the benefits? That is an uncomfortable position for a medicines regulator.